Anthropic Mithril acquisition: Anthropic buys a one-person muscular dystrophy startup and starts its own drug programs

The Anthropic Mithril acquisition came to light on October 27, 2026, inside a long Anthropic post titled "Early progress on accelerating drug development with Claude." Anthropic said it has acquired Mithril Medicine, which it calls "a one-person company" developing treatments for two rare forms of muscular dystrophy, and that "we've also begun drug discovery efforts of our own." It's Anthropic's second known biotech purchase of 2026, and it moves the company from selling AI-for-science tools toward running drug programs itself. Anthropic didn't disclose a price. Its earlier lab results, such as the scorpion-toxin binders Claude designed, are covered in our story on that experiment.

This story is based on Anthropic's October 27, 2026 post and Mithril's October 26 technical report, Anthropic's June 30 Claude Science announcement, its October 26 S-1, Endpoints News's October 27 report, and The Next Web's coverage of the Coefficient Bio deal and of Reuters' wet-lab report, checked October 28 and 29, 2026. Every result below is reported by Anthropic or its partners.

The short version

• What Anthropic bought: Mithril Medicine, a one-person startup working on rare childhood muscular dystrophies. Founder Cody Tranbarger now works at Anthropic.
• Terms: none disclosed by Anthropic. Endpoints News reported that Mithril was backed by Atlas Venture.
• The science: an injected "bispecific bridging antibody" for LAMA2-related congenital muscular dystrophy, tested so far only in a small mouse pilot that isn't peer reviewed.
• The timeline: if the candidates hold up, Anthropic says, a drug could be ready for human trials "as soon as late 2028."
• The partners: the same post reports early results with six drug developers, including Bristol Myers Squibb, Generate Biomedicines and Enveda.

What is Mithril Medicine?

Mithril Medicine is a small rare-disease startup founded by Cody Tranbarger. According to Anthropic, Tranbarger used Claude to manage contracts, logistics and experiments with 11 external labs, and took a possible treatment for one form of muscular dystrophy to "promising results in mice in less than 18 months." He now works at Anthropic and plans several new programs, the company says.

Endpoints News, which reported the deal on October 27, called Mithril "a one-person stealth biotech backed by Atlas" and said its founder ran the "Professor Oak" account on X. The rest of Endpoints' article is behind a paywall.

Mithril's technical report, dated October 26, 2026 and marked "Not peer reviewed," names the target: LAMA2-related congenital muscular dystrophy, a rare inherited muscle disease, with α-dystroglycanopathies as a second target. The candidate is a bispecific antibody designed to bridge the muscle fiber and the surrounding membrane, given by injection rather than as a gene therapy.

What results has Mithril reported?

Only early animal data, by its own account. In a pilot study in a mouse model of the disease, the report says, "mice treated with the tetravalent construct developed about twice the peak force and grip strength of vehicle-treated mice." The groups were small: seven treated mice and four untreated disease-model mice were tested in that comparison. The report says "the safety of a bispecific bridging antibody itself remains to be established," and it notes that no linker-based treatment for the disease had entered a clinical trial as of October 2026.

Anthropic's post says that if the drug candidates "continue to hold up," a drug could be ready for human trials "as soon as late 2028." That is a projection, not a filing; no regulator has been named.

What did Anthropic pay for Mithril?

Anthropic hasn't said. Neither the October 27 post nor the technical report gives a price, a structure or a closing date, and Endpoints' visible headline and summary don't either. Anthropic's IPO filing, filed on October 26, says the company intends to "selectively pursue acquisitions" and that "we do not have agreements or commitments for any material acquisitions or investments at this time"; our S-1 breakdown covers the rest of that document. The S-1 doesn't name Mithril, and as of October 29, EDGAR's full-text search found no mention of Mithril in any Anthropic filing, and no amended S-1 had been filed.

What does Anthropic claim from its six drug-development partners?

Anthropic says its scientists have had "deep research partnerships with six organizations developing new medicines." Each result below is reported by Anthropic and the named partner, mostly from lab work, and several come with partner technical reports. None has been independently replicated.

Last verified: October 28, 2026

Anthropic says the work is "still at an early stage." The post doesn't name which Claude model was used for each result.

How does Mithril fit Anthropic's life-sciences push?

It's the latest of several moves in 2026:

• April 2026: Anthropic bought Coefficient Bio, a startup with fewer than 10 people, in an all-stock deal worth "just over $400 million," as first reported by The Information, according to The Next Web. Anthropic's S-1 confirms that it completed the acquisition in April 2026 and that the consideration was 15.4 million shares of Class A common stock, part of it tied to share revesting for continuing employees; the filing gives no dollar value.
• June 30, 2026: Anthropic launched Claude Science, "an AI workbench for scientists," in beta for Pro, Max, Team and Enterprise users on macOS and Linux.
• September 18, 2026: Reuters reported that Anthropic had set up a biology wet lab in the Bay Area. Its head of life sciences, Eric Kauderer-Abrams, confirmed the lab, while a spokesperson said it was "not for drug discovery specifically," as relayed by The Next Web.
• October 27, 2026: Anthropic disclosed the Mithril acquisition and said it had begun drug discovery of its own, starting with "rare childhood forms of muscular dystrophy," and plans "to scale this work up substantially."

Anthropic isn't alone: Kevin Weil's Warp Sciences raised $215 million for an AI-and-robotics chemistry lab aimed at drug-development work, as our Warp Sciences story reports.

What's confirmed, reported and uncertain

• Confirmed by Anthropic: the Mithril acquisition, Tranbarger's move to Anthropic, the start of in-house drug discovery, the six partnerships and their reported results, and the "late 2028" earliest trial target. All results are vendor- and partner-reported. The Coefficient Bio acquisition and its 15.4 million-share consideration are confirmed in Anthropic's S-1.
• Reported: Atlas Venture backing and Tranbarger's X account (Endpoints News); the Coefficient Bio dollar value (The Information, via The Next Web); the wet lab (Reuters, via The Next Web).
• Uncertain: the price and terms of the Mithril deal; whether the antibody is safe or works in people; which Claude models produced the partner results.